MedElevator
Войти в исследования Molecular neurobiology · 2026
Cocaine Use Disorder: Neuropathology and Exploratory Treatments.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almeida Amanda, Warlick Halford G, Arain Arisha, Arora Simran, Boldt Erick, Chandramohan Causicaa, Chandramohan Prathmica, Fogel Maiah, Gogerdchian Hamid, Hajivandi Borna, Jafarmadar Armena, Koleng Marianne, Paparozzi Jeremy, Rodriguez Jorge Rubinos, Rodriguez Sergio, Santaya Melissa, Sardinas Madeline, Simon Leah, Wahid Rafay, Wahid Talha, Davis Kelley
Аннотация
RATIONALE: Cocaine use disorder (CUD) is a clinically recognized condition characterized by compulsive drug-seeking behavior and neurobiological dysfunction. It results from complex interactions between neurotransmitter imbalances and neuroinflammatory processes. Given the growing understanding of its immunopathological effects, it is crucial to investigate the diverse mechanisms of CUD and assess new therapeutic approaches that target both neurochemical and inflammatory pathways.
OBJECTIVES: The main aim of this review is to gather information on the psychopharmacological mechanisms, neuroinflammatory features, and impact of cocaine hydrochloride on neurotransmitters, especially monoamines involved in CUD.
METHODS: As the Food and Drug Administration has not approved any drugs for the treatment of CUD, we reviewed novel therapeutic agents and emerging treatment strategies for CUD from preclinical studies. We analyzed the current literature on CUD, focusing on its pathophysiology, neuroinflammation, and treatment. Relevant studies were sourced from PubMed, NCBI, AccessMedicine, and Clinical Key databases.
RESULTS: Preclinical findings have suggested potentially promising treatments for CUD, including L-DOPA, M. pruriens, monoamine precursors, TA-CD (cocaine vaccine), and immunotherapy. In addition, these treatment modalities have had some success in subjects given their effects on targeting neuroinflammation.
CONCLUSIONS: Targeting neuroinflammation with drugs and other modalities with specific therapeutic approaches may hold promise for treating patients with CUD. However, further research is needed as no FDA-approved treatment is yet available. These novel approaches may help reduce incidence rates within the CUD patient population and should be investigated further.
OBJECTIVES: The main aim of this review is to gather information on the psychopharmacological mechanisms, neuroinflammatory features, and impact of cocaine hydrochloride on neurotransmitters, especially monoamines involved in CUD.
METHODS: As the Food and Drug Administration has not approved any drugs for the treatment of CUD, we reviewed novel therapeutic agents and emerging treatment strategies for CUD from preclinical studies. We analyzed the current literature on CUD, focusing on its pathophysiology, neuroinflammation, and treatment. Relevant studies were sourced from PubMed, NCBI, AccessMedicine, and Clinical Key databases.
RESULTS: Preclinical findings have suggested potentially promising treatments for CUD, including L-DOPA, M. pruriens, monoamine precursors, TA-CD (cocaine vaccine), and immunotherapy. In addition, these treatment modalities have had some success in subjects given their effects on targeting neuroinflammation.
CONCLUSIONS: Targeting neuroinflammation with drugs and other modalities with specific therapeutic approaches may hold promise for treating patients with CUD. However, further research is needed as no FDA-approved treatment is yet available. These novel approaches may help reduce incidence rates within the CUD patient population and should be investigated further.